Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Down 36.6% in November

Achilles Therapeutics plc (NASDAQ:ACHL) was the recipient of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 136,700 shares, a drop of 36.6% from the November 15th total of 215,700 shares. Currently, 0.4% of the shares of the company are sold short. Based on an average daily trading volume, of 673,800 shares, the days-to-cover ratio is currently 0.2 days.

Achilles Therapeutics Price Performance

Shares of ACHL stock opened at $0.99 on Friday. The firm has a market cap of $40.68 million, a PE ratio of -0.60 and a beta of 1.37. Achilles Therapeutics has a 12 month low of $0.63 and a 12 month high of $1.76. The stock has a 50 day moving average of $1.03 and a 200-day moving average of $0.90.

Hedge Funds Weigh In On Achilles Therapeutics

An institutional investor recently raised its position in Achilles Therapeutics stock. XTX Topco Ltd boosted its holdings in shares of Achilles Therapeutics plc (NASDAQ:ACHL) by 239.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 51,660 shares of the company’s stock after purchasing an additional 36,441 shares during the period. XTX Topco Ltd owned about 0.13% of Achilles Therapeutics worth $42,000 as of its most recent SEC filing. Institutional investors own 56.38% of the company’s stock.

Achilles Therapeutics Company Profile

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.